Joint Oversight Committee. There shall be a Joint Oversight Committee to provide oversight of all planning development and implementation of the components of this Agreement. The committee will be composed of 4 members—the CEO, the PSASA President, and two others, one designated by the Board and one designated by PSASA, which must meet within 15 days of ratification of the Agreement. The committee will, among other things: • Define the full scope and objectives of the components of this Agreement • Assess the needs of the district for programs needed by students and the capacity of the professional staff to meet those needs • Identify educational and professional activities that need to be engaged in by staff, evaluated for effectiveness, and to serve as a basis for compensation decisions • Create and oversee a system for ensuring reliability and validity of evaluations conducted by Unit II evaluators including, but not limited to observations to ensure inter-rater reliability. • If there are worksites that have experienced significant change in the proportion of teachers receiving lower evaluations as compared to the previous school year and review is conducted including the examination of the evidence used in reaching the decisions, then a representative of PSASA shall be included in any review conducted by representatives appointed by the CEO and the President of the BTU. • Create and oversee the process to select members to Professional Review committees, designate their responsibilities, and provide general operating oversight of their work o Unit II members will apply to the President of PSASA consistent with the application process developed by the Joint Oversight Committee to serve on Review committees. • If necessary, create subcommittees including but not limited to a subcommittee to ensure that at least one peer reviewer is within the same school configuration (e.g. elementary/middle, middle, and high school) and to ensure that at least one peer reviewer on a given committee has expertise relevant to the Unit II member being reviewed (e.g., Title I, Special Ed, Network, etc. for Central Office employees). • Review and affirm the administrative and infrastructure capacity of the system and certify that the program is ready for implementation o The infrastructure must provide the ability for Unit II members to view all data related to quality control and be integrated into the registration process for Leadership Units (LUs) • Certify that the district has the resources to i...
Joint Oversight Committee. 10.1 The parties will (except to the extent that the Dispute Resolution Procedure is applied) address all ongoing issues hereunder through the process detailed in Clause 13 of the Amended and Restated Service Bureau Software Services Agreement.
Joint Oversight Committee. A joint oversight committee will be established to oversee the implementation of the Voluntary Disability Insurance Plan, Paid Family Leave Plan, Long Term Disability Plan IV and Return to Work agreement. The committee shall have the authority to make recommendations to the Company’s Chief Negotiator and the Union Business Manager pertaining to: Contractual impacts that may result from this agreement. Quarterly review of employees who may become eligible for LTD Plan IV and Stay at Work/Return to Work benefits. In an effort to create opportunities to Stay at Work or Return to Work, the joint oversight committee may recommend current job vacancies and/or recommend newly created positions on a case-by-case basis. The third party administrator for the Short-Term Disability/Paid Family Leave benefits.
Joint Oversight Committee. (a) GNE shall have full responsibility for and control of pre-clinical and clinical development and commercialization of Licensed Products. Within thirty (30) days of the Effective Date, the Parties will establish a Joint Oversight Committee (the "JOC") to review progress on the pre-clinical portion of the product development contemplated by this Agreement. The goal of the JOC is to facilitate the exchange of information and the coordination between the Parties relating to the development of Licensed Products. The JOC will be composed of two representatives of each Party, who shall be appointed (and may be replaced at any time) by such Party on written notice to the other in accordance with this Agreement. Such representatives shall include individuals within the organization of each Party with expertise in biopharmaceutical drug development. Any member of the JOC may designate a substitute to attend and perform the functions of that member at any meeting of the JOC. The JOC will meet at least twice annually during the Development Period and at least once annually following the Development Period but prior to commencement of a Phase III clinical trial, or at any other frequency agreed by the JOC. After commencement of a Phase III clinical trial, the JOC shall meet when and if agreed to by the JOC.
(b) Without limiting the foregoing, the JOC shall perform the following functions with regard to pre-clinical development of the Antibodies:
(i) be responsible for allocating development duties among the Parties, for reviewing development plans, for exchanging information and facilitating cooperation and coordination between the Parties, and for implementing all activities approved by the JOC or GNE, as the case may be; and
(ii) receiving and reviewing the annual reports to be delivered by each party pursuant to Section 3.7 below.
Joint Oversight Committee. 15.1 The parties will address all issues arising under this Agreement (to the extent that the dispute resolution procedure in Clause 16 has not been applied) through the joint oversight committee created pursuant to the Service Bureau Agreement.
Joint Oversight Committee. A joint Company-Union Oversight Committee will be created and will include up to three members selected by the Union and up to three members selected by the Company. This Committee will address issues related to the implementation of this agreement.
Joint Oversight Committee. Within thirty (30) days of the Effective Date, the Parties shall form a governance committee (the “Joint Oversight Committee” or “JOC”) in order to exchange information, review and discuss CTI’s plans regarding the Product in the Territory, discuss material Product developments (including, clinical trial results, FDA and other regulatory communications, intellectual property status, prescription and Net Sales data, and manufacturing and supply information), track use of the Service Payments Obligation, and monitor the activities and progress of CTI hereunder (including compliance with Section 3.4 obligations). Each of CTI and PharmaBio shall bear its own costs and expenses arising from its respective activities under this Article IV, including attendance and participation in meetings of the Joint Oversight Committee. The JOC shall have no decision making authority (including no authority to amend or contradict the Transaction Documents), but shall provide a regularly scheduled forum for the Parties to exchange and discuss information regarding the Product and their relationship.
Joint Oversight Committee. PeoplePC and Ford shall establish a joint oversight committee to develop, oversee and coordinate the implementation and roll-out of the Ford Employee Connectivity Program ("
Joint Oversight Committee. (a) No later than (30) days after the Effective Date, the Parties shall establish the Joint Oversight Committee, which shall facilitate communications between the Parties, and monitor and provide strategic oversight with respect to the activities under this Agreement, including the Development, Manufacture, and Commercialization of the Product in the Territory, all in accordance with this Section 3.2. The JOC shall have no decision-making authority.
(b) No later than thirty (30) days after the Effective Date, each Party shall appoint three (3) representatives to the JOC, each of whom will have sufficient seniority within the applicable Party or its Affiliates and knowledge and expertise in the Development, Manufacturing, and Commercialization of products similar to the Product to make decisions arising within the scope of the JOC’s responsibilities. The JOC may change its size from time to time by mutual consent of its representatives; provided, that the JOC will consist at all times of an equal number of representatives of each of CBMG and Novartis. Each Party may replace its JOC representatives at any time upon written notice to the other Party. The JOC may invite non-representatives to participate in the discussions and meetings of the JOC; provided, that such participants are bound under written obligations of confidentiality no less protective of the Parties’ Confidential Information than those set forth in this Agreement. The JOC will be chaired by one (1) chairperson designated by Novartis and one (1) chairperson designated by CBMG (collectively, the “JOC Co-Chairs”), whose responsibilities will include conducting meetings, including, when feasible, ensuring that objectives for each meeting are set and achieved. Responsibility for running each meeting of the JOC will alternate between the JOC Co-Chairs from meeting-to-meeting, with Novartis’s JOC Co-Chair running the first meeting. The JOC Co-Chairs will prepare and circulate agendas and to ensure the preparation of minutes. The JOC Co-Chairs shall have no additional powers or rights beyond those held by the other JOC representatives.
Joint Oversight Committee. A. As soon as practicable, but no later than the first day of school in the 2011-‐2012 school year, the DOE and UFT shall establish a joint committee consisting of two members selected by the UFT and two members selected by the DOE (the “Joint Oversight Committee”) to oversee and support the implementation of this Agreement and the Transformation and Restart Schools.
B. The Joint Oversight Committee shall have the authority to (i) hear concerns regarding the manner in which this Agreement is being implemented by the parties and (ii) recommend solutions to problems or suggest resources to provide technical assistance. The Joint Oversight Committee shall not have the authority to direct any DOE employee to take any action.
